Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 12/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547680 | 1.00 | PDE2A (0.35) | PDE2ACYP26A1UTS2RAKR1C3AKR1C2 | |
| SCHEMBL12241678 | 0.89 | JAK3 (0.36) | PDE2ACYP26A1UTS2RTEAD1 | |
| SCHEMBL1743596 | 0.84 | TRPV1 (0.36) | PDE2AAKR1C3AKR1C2 | |
| SCHEMBL1742760 | 0.80 | TEAD1 (0.35) | PDE2ACYP26A1AKR1C3AKR1C2TEAD1 | |
| SCHEMBL4839775 | 0.80 | TEAD1 (0.37) | PDE2ACYP26A1UTS2RAKR1C3AKR1C2 | |
| SCHEMBL5018934 | 0.80 | AKR1C3 (0.39) | PDE2ACYP26A1AKR1C3AKR1C2TEAD1 | |
| SCHEMBL1742763 | 0.77 | NOS3 (0.33) | PDE2ACYP26A1UTS2R | |
| SCHEMBL1595429 | 0.77 | PDE2A (0.39) | PDE2AAKR1C3AKR1C2 | |
| SCHEMBL1744800 | 0.77 | PDE2A (0.35) | PDE2ACYP26A1 | |
| SCHEMBL1595431 | 0.77 | PDE2A (0.39) | PDE2AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | PDE2A 2083/4885CYP26A1 3626/4885UTS2R 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.